CANF Can Fite Biopharma Ltd ADR

USD 3.47 0.00 0
Icon

Can Fite Biopharma Ltd ADR (CANF) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 3.47

0.00 (0.00)%

USD 0.01B

0.12M

N/A

N/A

Icon

CANF

Can Fite Biopharma Ltd ADR (USD)
COMMON STOCK | NYE
USD 3.47
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.01B

N/A

USD 3.47

Can Fite Biopharma Ltd ADR (CANF) Stock Forecast

N/A

Based on the Can Fite Biopharma Ltd ADR stock forecast from 0 analysts, the average analyst target price for Can Fite Biopharma Ltd ADR is not available over the next 12 months. Can Fite Biopharma Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Can Fite Biopharma Ltd ADR is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Can Fite Biopharma Ltd ADR’s stock price was USD 3.47. Can Fite Biopharma Ltd ADR’s stock price has changed by +43.39% over the past week, -4.41% over the past month and +15.28% over the last year.

No recent analyst target price found for Can Fite Biopharma Ltd ADR
No recent average analyst rating found for Can Fite Biopharma Ltd ADR

Company Overview Can Fite Biopharma Ltd ADR

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, whic...Read More

https://www.canfite.com

10 Bareket Street, Petah Tikva, Israel, 4951778

8

December

USD

USA

Adjusted Closing Price for Can Fite Biopharma Ltd ADR (CANF)

Loading...

Unadjusted Closing Price for Can Fite Biopharma Ltd ADR (CANF)

Loading...

Share Trading Volume for Can Fite Biopharma Ltd ADR Shares

Loading...

Compare Performance of Can Fite Biopharma Ltd ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CANF

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Can Fite Biopharma Ltd ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S 0.00 (0.00%) USD634.05B 49.43 4.92

ETFs Containing CANF

Symbol Name CANF's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Can Fite Biopharma Ltd ADR (CANF) Stock

Stock Target Advisor's fundamental analysis for Can Fite Biopharma Ltd ADR's stock is Bearish.

Unfortunately we do not have enough data on CANF's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on CANF's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on CANF's stock to indicate if its overvalued.

The last closing price of CANF's stock was USD 3.47.

The most recent market capitalization for CANF is USD 0.01B.

Unfortunately we do not have enough analyst data on CANF's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Can Fite Biopharma Ltd ADR's stock.

As per our most recent records Can Fite Biopharma Ltd ADR has 8 Employees.

Can Fite Biopharma Ltd ADR's registered address is 10 Bareket Street, Petah Tikva, Israel, 4951778. You can get more information about it from Can Fite Biopharma Ltd ADR's website at https://www.canfite.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...